Who are GentiBio's investors?

GentiBio's investors include Novartis Venture Fund, OrbiMed, JDRF T1D Fund, RA Capital.

How much funding has GentiBio raised?

GentiBio has disclosed $20M raised across 1 of its 2 known rounds.

GentiBio

Founded 2020 · 43 employees on LinkedIn · 4 known investors

Find your way into GentiBio

Paths you didn't know you had: your email and LinkedIn already hold routes to the GentiBio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

Biotech Healthtech Medical Devices

Founders & leadership

GentiBio was founded in 2020 by Jane Buckner, Chandra Patel, David Rawlings, and Andy Scharenberg.

Jane BucknerScientific Co-founder (President, Benaroya Research Institute)

Chandra Patel Co-founder & SVP, Research and Development OperationsChandra Patel has led preclinical research and development programs across cell therapy, gene therapy, and small molecule therapeutics, with expertise in hematology and autoimmune disease. Prior to GentiBio, Patel managed academic collaborations and regulatory engagement with the FDA and European medicines authorities.

David RawlingsScientific Co-founder and Senior Scientific Advisor

Andy ScharenbergScientific Co-founder, SAB Chair

Andy WalkerPresident and CEO

Tom WickhamChief Scientific Officer

Mark Bach Chief Medical OfficerMark Bach is Chief Medical Officer at GentiBio with over 30 years of pharmaceutical experience spanning clinical sciences, clinical research operations across Asia-Pacific and global markets, and prior biotech leadership roles including involvement in an IPO process.

Investors · 4

Novartis Venture Fund✓ confirmed by GentiBioBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · funding news · gentibio.com · Not right? Tell us

OrbiMed✓ confirmed by GentiBioNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · funding news · gentibio.com · the VCSheet dataset · Not right? Tell us

JDRF T1D Fundlisted by JDRF T1D FundBoston

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · gentibio.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$20M disclosed across 1 of 2 rounds · 2020–2021

$20MSeed FundingAug 2020 · 2 sources
Novartis Venture Fund, OrbiMed, RA Capital Management, L.P.
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

AskBioAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

Companies working in the same space as GentiBio.

In the news

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases - GentiBiogentibio.com · Aug 2020

Frequently asked questions

What does GentiBio do?: GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Who founded GentiBio?: GentiBio was founded by Jane Buckner, Chandra Patel, David Rawlings, Andy Scharenberg in 2020.
Who are GentiBio's investors?: GentiBio's investors include Novartis Venture Fund, OrbiMed, JDRF T1D Fund, RA Capital.
How much funding has GentiBio raised?: GentiBio has disclosed $20M raised across 1 of its 2 known rounds.